{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-223743","form_type":"8-K","ticker":"DBVT","cik":"0001613780","company_name":"DBV Technologies S.A.","filed_at":"2024-09-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.777889+00:00","generated_at":"2026-05-31T02:26:55.460661+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"DBV completes VITESSE Phase 3 screening early; topline data expected Q4 2025","bullets":["Screening closed in August 2024, ahead of schedule; enrollment exceeded original goal.","VITESSE enrolled >600 peanut-allergic children ages 4-7 across 86 sites in U.S., Canada, Europe, UK, Australia.","Subjects randomized 2:1 to active Viaskin Peanut Patch vs placebo; 12-month study.","Largest immunotherapy trial in peanut allergy; DBV targets Biologic License Application submission after data.","Topline efficacy and safety results from VITESSE expected by Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-223743","json":"https://secwatch.observer/filing/0001193125-24-223743.json","markdown":"https://secwatch.observer/filing/0001193125-24-223743.md","text":"https://secwatch.observer/filing/0001193125-24-223743.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1613780/000119312524223743/0001193125-24-223743-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1613780/000119312524223743/d837908d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T02:26:55.460661+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}